Sona Nanotech and BioVaxys partner to develop next-generation cancer therapies

Proactive - Interviews for investors

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

8d ago 4:41

MP3•Episode home

Sona Nanotech CEO David Regan joined Steve Darling from Proactive to announce a groundbreaking Research Agreement with BioVaxys Technology Corp. aimed at developing a novel class of cancer therapeutics. The collaboration unites two innovative technologies: BioVaxys’ Immune Educating Platform (DPX) and Sona’s Targeted Hyperthermia Therapy (THT), powered by proprietary gold nanorod technology. Sona’s THT is an advanced photothermal cancer therapy that uses near-infrared light to generate localized heat within solid tumors. This thermal energy is delivered through Sona’s biocompatible gold nanorods, which not only destroy tumor cells but also stimulate a strong immune response—a crucial factor in combating cancer recurrence. The research will explore how BioVaxys’ DPX platform, known for priming the innate immune system, can further enhance this immune response when used in tandem with THT. “The potential synergy between these two technologies could significantly accelerate the immune system’s ability to recognize and attack tumors,” said Regan. One area of focus is the use of DPX to deliver tumor-specific neoantigens—unique proteins that emerge after cancer cell mutations and are absent from healthy tissues. Since THT can induce these mutations and neoantigen expression, pairing it with DPX could dramatically improve immune system targeting and treatment efficacy. Essentially, THT triggers changes in tumor cells, and DPX packages those changes for the immune system to attack. The research initiative is supported by the Giacomantonio Immuno-Oncology Research Group, which will fund the preclinical studies. Both companies will contribute their core technologies to the collaboration. Any new therapeutic candidate developed will be jointly owned and prosecuted by BioVaxys and Sona, with a commercialization agreement planned ahead of a potential Phase 1 clinical trial. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerResearch #MelanomaTreatment #BioVaxys #DPXTechnology #ClinicalTrials #TargetedTherapy #GoldNanorods #OncologyInnovation #ProactiveInvestors

605 episodes

#Trading #Business News #Business #News #Proactive Investors #Gold #Cannabis #Battery Metals #Chief Executive #Biotech #Natural Resources #Bitcoin #Cryptocurrency #Interviews #Investing #Investment Research #Mining #Retail Investment #Technology